Myeloproliferative Neoplasms News

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, highlighted recent developments and available treatments in myeloproliferative neoplasms care.

Several hematologists will be honored during this year’s ASH Annual Meeting.

CHICAGO — Interim results from a phase 2 study showed positive survival outcomes for individuals who underwent peripheral blood stem cell transplantation for hematologic malignancies.

Participation in cancer-related clinical trials could increase dramatically if researchers screened and recruited individuals using routine care patient-reported outcomes, according to results published in JAMA Oncology.

The amount of autologous and allogeneic hematopoietic stem cell transplants for hematologic disorders has increased over time in tandem with longer survival, according to results of an observational study.

Individuals prescribed the antidiabetes treatment metformin less likely developed a myeloproliferative neoplasm —potentially also reducing a person’s chances for developing certain cancers — according to data published in Blood Advances.

AI could have the ability to answer some patient questions on cancer instead of clinicians, reducing clinician burdens and improving access to care, according to study results published in JAMA Oncology.

Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.

An FDA advisory committee voted 12-2 that the benefits of the investigational therapy imetelstat outweigh the risks for the treatment of transfusion-dependent anemia in certain adults with myelodysplastic syndromes.

Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.